Advisory Alpha’s Sarepta Therapeutics SRPT Stock Holding History

Advisory Alpha’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,320	Closed	-$209K	–	437
2024 Q2	$209K	Sell	1,320 -1,370	-51%	-$176K	0.01%	372
2024 Q1	$348K	Hold	2,690	–	–	0.01%	271
2023 Q4	$259K	Hold	2,690	–	–	0.01%	288
2023 Q3	$326K	Hold	2,690	–	–	0.02%	228
2023 Q2	$308K	Hold	2,690	–	–	0.02%	251
2023 Q1	$371K	Hold	2,690	–	–	0.02%	207
2022 Q4	$349K	Sell	2,690 -185	-6%	-$21.4K	0.02%	192
2022 Q3	$318K	Hold	2,875	–	–	0.02%	196
2022 Q2	$216K	Hold	2,875	–	–	0.02%	234
2022 Q1	$225K	Sell	2,875 -225	-7%	-$17.2K	0.01%	246
2021 Q4	$279K	Hold	3,100	–	–	0.02%	221
2021 Q3	$287K	Sell	3,100 -150	-5%	-$11.6K	0.02%	210
2021 Q2	$253K	Sell	3,250 -140	-4%	-$10.6K	0.02%	168
2021 Q1	$253K	Sell	3,390 -150	-4%	-$13.8K	0.03%	153
2020 Q4	$604K	Sell	3,540 -20	-0.6%	-$2.96K	0.12%	48
2020 Q3	$519K	Hold	3,560	–	–	0.11%	46
2020 Q2	$562K	Hold	3,560	–	–	0.12%	54
2020 Q1	$411K	Hold	3,560	–	–	0.12%	58
2019 Q4	$444K	Hold	3,560	–	–	0.11%	75
2019 Q3	$288K	Hold	3,560	–	–	0.09%	87
2019 Q2	$531K	Hold	3,560	–	–	0.18%	62
2019 Q1	$423K	Hold	3,560	–	–	0.15%	65
2018 Q4	$452K	Buy	+3,560	New	+$445K	0.21%	54

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisory Alpha's SRPT Position: Q3 2024 in Review

Advisory Alpha sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 1,320 shares — an estimated $209K sold.

Advisory Alpha first reported a position in SRPT in Q4 2018 and held it in 23 quarters. The position peaked at $604K in Q4 2020. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Advisory Alpha reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
Advisory Alpha sold 1,320 Sarepta Therapeutics shares in Q3 2024, an estimated $209K.
Advisory Alpha first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 23 quarters.
Advisory Alpha's Sarepta Therapeutics position peaked at $604K in Q4 2020.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Advisory Alpha's 13F filing for Q3 2024, filed 12 Nov 2024.